There is evidence that caffeine increases alertness and reduces fatigue. This may be especially so in low arousal situations (e.g. working at night or for prolonged hours). Caffeine has also been found to improve performance on vigilance tasks and simple tasks requiring sustained response. Again, these effects are often clearest when alertness is reduced, although there is evidence that benefits may still occur when the individual is unimpaired. Most studies to date have investigated the behavioural effects of caffeine in laboratory experiments using artificial tasks. In the current study 3 mg/kg caffeine was found to improve steering accuracy in a 1 h simulated drive. Measures of mood and performance on a sustained attention task also showed the benefits of caffeine. These findings suggest that laboratory results reflect a general benefit of caffeine that may also be observed in real-life situations. Other evidence examining the effects of caffeine on performance efficiency over the working day has shown the benefits of caffeine consumption on measures of sustained attention and alertness. This study also provided evidence suggesting that caffeine is often consumed when alertness is low to maximise alertness and performance efficiency. The implications of these findings for road safety are also considered. Copyright 2001 John Wiley & Sons, Ltd.

These results suggest that previous findings from studies using a large single dose may be applicable to normal patterns of caffeine consumption.

There have been numerous studies on the effects of caffeine on behaviour and cardiovascular function. It is now important to clarify the mechanisms that underlie such effects, and the main objective of the present study was to investigate whether changes in central noradrenaline underlie some of the behavioural and cardiovascular effects of caffeine. This was examined using a clonidine challenge paradigm. Twenty-four healthy volunteers were assigned to one of four conditions: (i) clonidine/caffeine; (ii) clonidine/placebo; (iii) placebo/caffeine: (iv) placebo/placebo. Baseline measurements of mood, cognitive performance, saccadic eye movements and cardiovascular function were recorded. Subsequently, volunteers were given either clonidine (200 microg) or placebo and consumed coffee containing caffeine (1.5 mg/kg) or placebo. The test battery was then repeated 30 min, 150 min and 270 min later. A second cup of coffee (with the same amount of caffeine as the first) was consumed 120 min after the first cup. The results showed that clonidine reduced alertness, impaired many aspects of performance and slowed saccadic eye movements; caffeine removed many of these impairments. Both clonidine and caffeine influenced blood pressure (clonidine reduced it, caffeine raised it) but the effects appeared to be independent, suggesting that separate mechanisms were involved. In addition, there were some behavioural effects of caffeine that were independent of the clonidine effect (e.g. effects on speed of encoding of new information) and these may reflect other neurotransmitter systems (e.g cholinergic effects). Overall, the results suggest that caffeine counteracts reductions in the turnover of central noradrenaline. This mechanism may underlie the beneficial effects of caffeine seen in low alertness states.

No abstract

The aim of the present study was to assess the impact of upper respiratory tract illnesses on efficiency at work. This was done using the 'after-effect' technique with measurements being taken before and after work and the difference between these giving an indication of efficiency over the day. All of the volunteers (N = 48) were tested when healthy to provide baseline data for simple reaction time and mood. When volunteers developed an upper respiratory tract illness (URTI) they (N = 16) repeated the procedure. Those who remained healthy over a three month period (N = 32) were recalled as healthy controls. In addition to the performance test and mood ratings the volunteers kept a sleep log and also rated how demanding the day had been and how much effort they had put in. The results showed that those with URTIs had slower reaction times and a more negative mood both before and after work. Illness did not have an effect on ratings of demand and effort. Those who were ill reported greater sleep disturbance but this could not account for the impaired performance or negative mood states. These results suggest that upper respiratory illnesses may impair performance and well-being at work.

The present study had two main aims. The first was to examine associations between psychosocial factors, health-related behaviours, regular level of caffeine consumption, time of day and levels of caffeine in saliva following acute caffeine challenges. The second aim was to determine whether individual differences in changes in performance following ingestion of caffeine were related to levels of caffeine in saliva. One hundred and forty-four young adults participated in the study. Questionnaires were administered prior to the study to measure psychosocial characteristics, health-related behaviours and habitual levels of caffeine consumption. Two double-blind acute caffeine challenges were then carried out 1 week apart. Volunteers were given either placebo or 1.5 or 3 mg/kg of caffeine on each occasion. The challenges were carried out at 8 : 00, 11 : 00, 14 : 00 or 18 : 00 h so that the impact of time of day could be assessed. In the week between the two challenges the volunteers consumed either caffeinated or decaffeinated products. This allowed investigation of the effects of caffeine withdrawal on caffeine metabolism. Prior to each caffeine challenge volunteers performed a range of tasks, and a baseline saliva sample was taken. The tasks were repeated 1 h after ingestion of the caffeine, with saliva samples being taken at the start and end of the 1 h test battery. The results showed that the level of caffeine in the saliva was a good indicator of the dose of caffeine consumed and of compliance with the withdrawal manipulation. Caffeine levels were not influenced by time of day, habitual caffeine consumption, psychosocial factors or health-related behaviours. Individual differences in caffeine levels in saliva were not related to the individual variation in the effects of caffeine on performance. Copyright 2001 John Wiley & Sons, Ltd.

The present study examined whether volunteers with common colds showed impairments in objective and subjective indicators of alertness. All the volunteers (N = 81) were tested when healthy to provide baseline data for mood, simple and choice reaction time tasks, and an anti-saccadic eye movement task. When subjects developed a cold (N = 17) they returned to the laboratory and repeated the procedure. Volunteers (N = 64) who remained healthy over a 10-week period were recalled as controls. The results showed that those with colds felt significantly less alert and had significantly slower simple and choice reaction times and eye movements. This extends earlier research and shows that electrophysiological measures may also be of use in assessing the behavioral changes induced by upper respiratory tract illnesses.

An experiment was carried out to determine whether idazoxan, a drug which increases the turnover of central noradrenaline, removes the malaise (reduced alertness, slower psychomotor performance) associated with upper respiratory tract illness (URTI). Eighty-one volunteers were tested when healthy and 17 returned to the laboratory when they developed URTIs. Those who remained healthy were then recalled as a control group. Volunteers were tested before and after receiving either idazoxan (40mg) or a lactose placebo. Idazoxan removed the URTI-induced slowing in a simple reaction time task and this group performed at a comparable level to the healthy group. No significant stimulant effect of idazoxan was found in the healthy subjects. The results suggest that at least part of the malaise induced by URTIs may reflect reductions in central noradrenaline and that this can be reversed by compounds such as idazoxan.